Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias [0.03%]
地中海贫血、镰状细胞病或其他贫血患者每日两次 deferiprone 的现实世界安全状况
Sujit Sheth,Ashutosh Lal,Abena Appiah-Kubi et al.
Sujit Sheth et al.
Iron overload is a significant cause of transfusion-related morbidity and mortality. Deferiprone (DFP) is an established oral iron chelator approved for the treatment of transfusional iron overload in patients with thalassemia, sickle cell ...
Cécile V Denis,Hachem Dich,Caterina Casari
Cécile V Denis
For the past decades, treatment for von Willebrand disease has essentially consisted of classic approaches and only in the past few years has the need for more innovative strategies been recognised. To address the needs of groups of patient...
Phase 2a randomized study to evaluate sapablursen in patients with non-transfusion dependent β-thalassemia intermedia [0.03%]
评估sapablursen治疗非输血依赖型β-地中海贫血中间型患者Ⅱ期临床试验
Ali Taher,Michael D Diamantidis,Antonis Kattamis et al.
Ali Taher et al.
Non-transfusion-dependent b-thalassemia intermedia (NTDT) is a genetically heterogeneous disorder characterized by decreased β-globin production in erythroid cells resulting from mutations in the β-globin gene that is not treated with tra...
Mohamed L Sorror,Andrew S Artz
Mohamed L Sorror
Engineering a TACI×CD3 Bispecific Antibody to Redirect T Cells Against Multiple Myeloma [0.03%]
工程化TACI×CD3双特异性抗体重定向T细胞对抗多发性骨髓瘤
Minchuan Zhang,Wai Fook Leong,Jianxin Huo et al.
Minchuan Zhang et al.
Immunotherapies targeting B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor (TNFR) superfamily, have demonstrated remarkable clinical efficacy in treating relapsed/refractory (RR) multiple myeloma (MM). Howeve...
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS [0.03%]
CEPHEUS研究中达雷妥尤单抗治疗不适合移植或延迟移植的多发性骨髓瘤新诊断患者：微小残留病的状态
Sonja Zweegman,Thierry Facon,Vania Hungria et al.
Sonja Zweegman et al.
In the phase 3 CEPHEUS study, daratumumab plus bortezomib/lenalidomide/dexamethasone (D‑VRd) increased overall MRD-negativity rates versus VRd in transplant-ineligible/transplant-deferred patients with NDMM. We present an expanded MRD anal...
Giacomo Maria Cerreto,Cecilia Carubbi,Marco Vitale et al.
Giacomo Maria Cerreto et al.
Richard C Becker
Richard C Becker
Epcoritamab in Richter Transformation: Insights from a Real-World Case Series [0.03%]
Epcoritamab治疗里特尔转化综合症的疗效：来自真实世界病例系列的见解
Vanja Zeremski,Sina Alexandra Beer,Frederik Damm et al.
Vanja Zeremski et al.
EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma [0.03%]
EuroNet-PHL-LP1：低风险结节性淋巴细胞为主型霍奇金淋巴瘤的完整切除与低剂量化疗比较研究
Ananth G Shankar,Judith Landman-Parker,Maurizio Mascarin et al.
Ananth G Shankar et al.
Children and adolescents with early-stage nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) have a 5-year event-free survival (EFS) of about 77% after complete lymph node resection and around 89% with anthracycline-containing chemothe...